In this pilot study, the Paradigm REAL-Time System was initiated safely and effectively in type 1 diabetes patients who were pump naïve using a stepwise educational protocol.

No abstract

Background/Aims Bitesized Teaching is an initiative that has worked successfully in Yorkshire and Derbyshire Mental Health Services for the last 5 years. It traditionally involves the delivery of high-impact, 10-minute tutorials on physical health topics, which take place once a week in the ward lunchtime handover period. This study evaluates an extension to the Bitesized Teaching scheme that incorporates delivering mental health-focused teaching topics to clinical staff on medical wards. Methods Bitesized Teaching was delivered by a mental health liaison team to medical ward staff with three rolling sessions in an hour. To monitor the improvement in knowledge, a pre and post 1–5 Likert scale questionnaire was used. Results The data showed that the knowledge from nursing staff improved on every topic. The topics ‘psychosis’ and ‘talking to people with psychosis’ had the greatest level of improvement in knowledge. Although the data reported a trend of increased knowledge, further analysis would need to explore the relevance the teaching topics had on clinical practice. Conclusions The results outline the need for general and paediatric nursing staff to receive specific mental health training with the intention to improve treatment outcome and wellbeing to patients admitted to hospital for acute medical care.

Objectives: To estimate cost of a sickle cell (SC) crisis, describe setting of care, and type of crisis; and compare costs of sequential crises among adult SC patients. Methods: We used a large US health plan claims database 2 Truven Commercial & Medicare Supplemental. Patients selected had $2 SC claims, presence of SC crisis between 2009-2016 (i.e., SC crisis diagnosis in emergency department [ED] or hospitalization), age $18y at index (i.e., first crisis), 1-year pre-and post-index continuous enrollment, and no crisis during 1-year pre-index period. Healthcare setting, type of crisis, and medical and pharmacy costs during the crisis encounter were measured. Costs of sequential crises were restricted to patients with fee-for-service insurance, adjusted for 2017 inflation, controlled for age, gender and comorbidities, and were compared using gamma models. Results: There were 1,583 patients (1,234 fee-for-service), mean (SD) age 38y ( 14) and 58% female. Mean number of crises during 1-year post-index was 1.9. Average time between crises was 4.2 months. Number of patients with 1+, 2+, 3+ and 4+ crises within 1 year were 1,583 (100%), 679 (43%), 306 (19%) and 160 (10%), respectively. Among these, 52%, 55%, 59% and 61% were hospitalized for the 1st-4th crises (average length of stay: w7 days), and the rest had ED visits. After one crisis, patients tended to have the same setting of care for their next crisis. Across all crises, majority were pain crises (w63%), followed by acute chest syndrome (w11%). Mean (SE) adjusted costs of 1st-4th crises were $12,685

maintained treatment effect from long-term evidence in other T2DM populations. Responder were primarily defined using a composite end-point that based on an HbA1c#7.0% threshold AND no weight gain AND no documented symptomatic hypoglycemia. The NNT was calculated to determine the average number of patients needed to be treated in order to gain one additional successful responder. Sensitivity analyses were performed to examine the robustness of results. Results: For the primary composite end-point, cost per responder results were 136,290 CNY for lixisenatide group, 231,487 CNY for Basal-Plus group, and 222,424 CNY for Basal-Bolus group. The NNT analysis showed that there was approximately one additional responder for every 7.65 and 8.74 patients treated with lixisenatide combined with basal insulin compared to Basal-Plus and Basal-Bolus, respectively. The sensitivity analysis proved the robustness of results. Conclusions: Lixisenatide combined with basal insulin is a cost-effective treatment alternative compared with Basal-Plus and Basal-Bolus for T2DM patients inadequately controlled by basal insulin in China.